CL2012000952A1 -
Using pirfenidone to treat a patient in need of it comprising avoiding or discontinuing the concomitant use or co-administration of a strong cyp1a2 inducer to avoid reduced exposure to pirfenidone.
- Google Patents
Using pirfenidone to treat a patient in need of it comprising avoiding or discontinuing the concomitant use or co-administration of a strong cyp1a2 inducer to avoid reduced exposure to pirfenidone.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/684,543external-prioritypatent/US8084475B2/en
Application filed by Intermune IncfiledCriticalIntermune Inc
Publication of CL2012000952A1publicationCriticalpatent/CL2012000952A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Uso de pirfenidona para tratar un paciente que la necesita que comprende evitar o discontinuar el uso concomitante o la co-administración de un inductor fuerte de CYP1A2 para evitar una exposición reducida a pirfenidona.Use of pirfenidone to treat a patient in need of it comprising avoiding or discontinuing concomitant use or co-administration of a strong CYP1A2 inducer to avoid reduced exposure to pirfenidone.
CL2012000952A2009-12-042012-04-13
Using pirfenidone to treat a patient in need of it comprising avoiding or discontinuing the concomitant use or co-administration of a strong cyp1a2 inducer to avoid reduced exposure to pirfenidone.
CL2012000952A1
(en)
Using pirfenidone to treat a patient in need of it comprising avoiding or discontinuing the concomitant use or co-administration of a strong cyp1a2 inducer to avoid reduced exposure to pirfenidone.
Use of a composition comprising an h1 antagonist, and an anti-tnf alpha compound to treat allergic conjunctivitis or allergic rhinitis in a human subject
Heterocyclic derivative compounds for use in the prevention or treatment of a flavivirus infection; method for its preparation; and pharmaceutical composition that includes them.
4- (8-methoxy-1 - ((1-methoxypropan-2-yl) -2- (tetrahydro-2H-pyran-4-yl) -1H-imidazo [4,5-C] quinolin-7-yl) -3,5-dimethylisoxazole and its use as a bromodomain inhibitor
Compounds derived from resolviin; pharmaceutical composition; use of the composition; pharmaceutical kit; pharmaceutical combination; use of the compounds in the treatment and / or prevention of an ophthalmic condition.
Combination comprising a smoothened inhibitor that is 2- (r) -4- (6-benzyl-4,5-dimethyl-pyridazin-3-yl) -2-methyl-3,4,5,6-tetrahydro-2h - [1,2`] -bipyrazinyl-5`-yl] -propan-2-ol and a mtor inhibitor; use to treat cancer.
Use of a nitrocatechol-derived compound, catechol-o-methyltransferase inhibitor, for the prevention and / or treatment of a transthyretin-associated amyloidosis
Pharmaceutical composition in aqueous solution comprising olopatadine and a compound derived from substituted quinoline, inhibitor of pde4; and use for the treatment of an allergic or inflammatory condition of the eye, nose, or skin.
Use of a pharmaceutical combination comprising a bis-thiazolium salt or one of its precursors and artemisinin or one of its derivatives, for the treatment and / or prevention of severe malaria; use of the pharmaceutical composition and the pharmaceutical kit comprising it.